Loxo Oncology $LOXO announced Q3 results. For the three-month period ended September 2016, EPS was -$0.82, missing the guidance by $0.08. As of September 2016, Loxo Oncology has aggregate cash, cash equivalents and investments of $156.5 million, compared to $153.9 million as of December�31, 2015.It expects cash burn of $48 to $52 million in 2016. Research and development expenses were $14.2 million for the third quarter of 2016, compared to $6.3 million for the third quarter of 2015.